PMVP News & Events

PMV Pharmaceuticals (PMVP) announced a transition on its board of directors. Laurie Stelzer, who has served as a member of the board since 2020, has been appointed chair of the board, succeeding Rich Heyman, effective at the company's 2026 annual meeting of stockholders on June 4. Heyman's term as a member and chair of the board will expire at the meeting, and Heyman will not stand for reelection. Stelzer is a seasoned CFO and public company board director, most recently serving as CFO at Kailera Therapeutics (KLRA).

"2025 was an important and productive year for PMV Pharma as we reported positive Phase 2 interim data from the registrational PYNNACLE clinical trial and made significant progress in enrolling the study," said David Mack, CEO. "We look forward to submitting an NDA in the first quarter of 2027 for rezatapopt in platinum-resistant/refractory ovarian cancer."

As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, compared to $183.3 million at December 31, 2024. Net cash used in operations was $73.6 million for the year ended December 31, 2025, compared to $51.3 million for the year ended December 31, 2024.